Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Squamous Cell Carcinoma of Head and Neck 22Uterine Cervical Neoplasms 19Lung Neoplasms 19Small Cell Lung Carcinoma 16Oropharyngeal Neoplasms 14Ovarian Neoplasms 12Carcinoma 10Urinary Bladder Neoplasms 9Stomach Neoplasms 9Mouth Neoplasms 9Laryngeal Neoplasms 9Fallopian Tube Neoplasms 9Hypopharyngeal Neoplasms 8Mesothelioma, Malignant 7Medulloblastoma 7Cholangiocarcinoma 7Breast Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Neuroblastoma 6Nasopharyngeal Carcinoma 6Gallbladder Neoplasms 6Ganglioneuroblastoma 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Lymphoid Interstitial Pneumonia 4Head and Neck Neoplasms 4Esophageal Neoplasms 4

Interventions

pembrolizumab 161Carboplatin 145Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 38sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Platinum × Clear all
NCT06351332 2026-05-22

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Dana-Farber Cancer Institute

Phase 1/2 Terminated
7 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

National Cancer Institute (NCI)

Phase 2 Completed
344 enrolled 11 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡